After scrapping a Phase II kidney disease study last month, it appears Angion Biomedica may be out of moves.
The Uniondale, NY-based biotech announced Monday afternoon that it would be looking into “strategic alternatives” — suggesting a potential merger, reverse merger and sale or licensing of its candidates as options it would be exploring. In the meantime, Angion will be shuttering its R&D work.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,